Zivkovic Samardzic has advised Manchester-based biotech firm APIS Assay Technologies Ltd on the Serbian aspects of its acquisition of BeoGenomics. CT Legal advised the unnamed seller of BeoGenomics on the deal.
According to Zivkovic Samardzic, APIS Assay combines "In Vitro Diagnostics expertise with integrated AI to develop biomarker-based diagnostic assays." BeoGenemics is a specialized software developer with expertise in bioinformatics and artificial intelligence.
According to Zivkovic Samardzic, “BeoGenomics has been developing both on-prem and secure cloud-based data analysis solutions – helping customers design, build and run custom-tailored genomics & proteomics pipelines. The start-up will be integrated into Manchester-based APIS, supporting the launch of a new BIOX Service Line as part of the company’s ongoing Biomarker Research and Development activities.”
Finally, according to Zivkovic Samardzic, "APIS develops new tests for the prediction, prevention, and diagnosis of disease from discovery to regulatory approval. The company’s business model is based on three pillars: biomarker diagnostics development, molecular diagnostic contract development, and applied bioinformatics."
Zivkovic Samardzic’s team included Partners Igor Zivkovski and Ana Popovic.
CT Legal's team included Partners Jovana Tomic and Anita Cakovic.